Navigation Links
Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
Date:9/6/2007

A partnership between Kent State University, Summa Health System and IC-MedTech Inc. has yielded an innovative liquid crystal technology that offers the promise of new drugs which may more effectively manage cancer and other diseases.

The American Cancer Society estimates that nearly 1.5 million new cases of cancer will be diagnosed this year. This crisis has caused the National Cancer Institute to establish a goal of eliminating suffering and death due to cancer by the year 2015.

Kent State University, Summa Health System and IC-MedTech Inc. have taken steps toward that goal. Their collaborative efforts have yielded an innovative liquid crystal technology that offers the promise of new drugs which may more effectively manage cancer and other diseases.

Dr. Chun-che Tsai, Kent State professor of chemistry; Dr. Jim Jamison, manager of Urology, Obstetrics and Gynecology Core Basic Research Laboratory for Summa Health System; and Mr. Tom Miller, president of IC-MedTech Inc., a California-based biotechnology company, have developed a new paradigm in drug discovery based on the pharmacologic properties of liquid crystals called Liquid Crystal Pharmaceuticals or LCPs.

Recently, the team gathered at Kent State Universitys Office of Technology Transfer to file applications for two new patents: one for a new LCP-based anti-tumor drug called Tolecine and another for a formulation that combines Tolecine and another LCP, Apatone®.

The path-breaking discoveries of Dr. Tsai and his colleagues offer compelling proof of the value of university research and the enormous good that can come from collaborations between universities and the private sector, says Kent State President Lester A. Lefton. As Kent State researchers tackle cancer and a host of other real-world ills and issues, they are bringing their leading-edge knowledge and creativity to our students and playing a significant role in economic development.

Though best known for their use in laptops, televisions and cell phones, liquid crystals also include families of organic substances that are essential for all life called lyotropic liquid crystals. Examples of lyotropic liquid crystals include DNA, proteins and cholesterol. LCPs are a unique class of lyotropic liquid crystals that represent novel drug candidates for the treatment of a wide range of diseases.

Mother nature is the ultimate chemist, says Tsai. Although we use creative and sophisticated computer modeling techniques to screen for our candidate compounds, Im always amazed at how nature puts it all together.

The most recent research involving LCPs has yielded a new investigational anti-tumor drug called Tolecine, a compound that also has antiviral and antibacterial applications. Created by Tsai, it has been shown to be even more effective than the current standard of care for herpes.

The teams second patent application involves a formulation that combines Tolecine and another LCP, Apatone®, which attacks cancer cells via multiple pathways to offer improved efficacy. Apatone® has been successfully tested in more than 30 human tumor cell lines at Summa and in a Phase I/IIa clinical trial, which demonstrated a delaying effect in the progression of end-stage cancer patients. In addition, the FDA granted Apatone® orphan-drug status for the treatment of metastatic, or locally advanced, inoperable bladder cancer in August 2007.

Unlike other chemotherapy drugs, TolecineTM and Apatone® have low toxicity and do not target dividing cells. Instead, they are activated by inflammation that occurs in and around tumor cells, sparing healthy cells. We want to kill cancer cells specifically without killing surrounding tissues, says Jamison.

Innovative, low-toxicity drugs such as Tolecine and Apatone® provide new hope in the battle against cancer and other diseases in the next few years. Research on LCPs provides a solid scientific foundation for generations of new drugs, says Miller. Adds Tsai: LCPs are an untapped frontier from which many new, exciting treatments are now emerging.


'/>"/>

Contact: Melissa Edler
medler@kent.edu
330-672-8589
Kent State University
Source:Eurekalert

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. NYU researchers simulate molecular biological clock
5. Researchers reveal the infectious impact of salmon farms on wild salmon
6. Researchers identify target for cancer drugs
7. Vital step in cellular migration described by UCSD medical researchers
8. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
9. UCSD researchers maintain stem cells without contaminated animal feeder layers
10. Researchers discover molecule that causes secondary stroke
11. Researchers find missing genes of ancient organism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
Breaking Biology Technology: